You are here

• Home
• About AstraZeneca US
• Newsroom

• Product news

The following shows headlines of all product-related news articles published within 12-months, starting from most recent.

• Pages
• 1
• 2
• 3
• Next

• • Jul 1, 2010
  • ARIMIDEX® (anastrozole) Tablets Savings Card provides instant savings to eligible patients  
• • Jun 29, 2010
  • CRESTOR® patent upheld by US Court  
• • Jun 26, 2010
  • 52-week study finds ONGLYZA™ (saxagliptin) when added to metformin was non-inferior to titrated glipizide when added to metformin in reducing glycosylated hemoglobin (HbA1c) in adults with type 2 diabetes mellitus  
• • Jun 26, 2010
  • ONGLYZA™ (saxagliptin) with metformin as initial combination therapy provided 76-week long-term glycemic control in treatment-naïve adults with type 2 diabetes  
• • Jun 2, 2010
  • FDA updates U.S. product labels for LABA-containing medications including AstraZeneca’s SYMBICORT  
• • Apr 30, 2010
  • FDA approved VIMOVO™ for arthritis patients at risk of developing NSAID-associated gastric ulcers  
• • Apr 16, 2010
  • AstraZeneca launches SEROQUEL XR® (quetiapine fumarate) for add-on treatment of major depressive disorder  
• • Mar 17, 2010
  • U.S. Food and Drug Administration accepts New Drug Application for once-daily fixed dose combination of ONGLYZA™ (saxagliptin) and extended release metformin for the treatment of type 2 diabetes mellitus in adults  
• • Mar 14, 2010
  • New analysis of JUPITER study evaluates link between high baseline levels of hsCRP and increased risk of cardiovascular events  
• • Mar 11, 2010
  • AstraZeneca comments on FDA Joint Advisory Committee meeting on post-marketing safety studies for the use of LABAs in asthma  

• Pages
• 1
• 2
• 3
• Next

Page tools

• Print
• Bookmark this page
• Subscribe to RSS news feed